Eli Lilly's Profits Surge in Q4 2024 with Diabetes and Obesity Medications

Eli Lilly anticipates releasing data from a late-stage trial on its next-generation weight loss drug Retatrutide earlier than expected later this year. Lilly's quarterly profit surged to $4.41 billion, doubling in the fourth quarter, primarily fueled by diabetes and obesity treatments. Mounjaro sales surpassed $11.54 billion for 2024, with Zepbound achieving sales of $4.9 billion in its inaugural year on the market. Mounjaro sales soared by 60% to $3.53 billion in the final quarter of 2024, with revenue increasing by 45% to $13.53 billion, aligning with projections.